Dong-a Pharmaceutical Co., Ltd

Dong-a Pharm. Co., Ltd.

Mezzion Pharma Co., Ltd.

Dong-a Pharmaceuticals Co. Ltd.

Dong-a Pharmtech Co., Ltd.

Dong-a St Co., Ltd.

Moohi Yoo

Kyung Koo Kang

Mi-Kyung Kim

Jae Young Lee

Woo Young Kwak

Heung Jae Kim

Jong Pil Min

Tae Hyun Yoon

Dong Sung Kim

Soon Hoe Kim

Byoung Ok Ahn

Moon-Ho Son

Chang Yell Shin

Joong In Lim

Seul Min Choi

Ik Yon Kim

Wonbae Kim

Song-Hyen Choi

Sung Hee Lee

Sang Deuk Lee

Tae Hyoung Kim

Sun Ki Chang

Geun Jho Lim

Mi Won Son

Won Bae Kim

Yong Man Park

Jae Sung Yang

Yu Na Chae

Hyun Joo Shim

Hyounmie Doh

Hee Chan Shin

Kyung Jin Park

Yoon Ji Kim

Geun Gho Lim

Soo Hyung Kang

Eun Kyoung Yang

Ji Myun Jang

Dong Goo Kim

Hyun Hee Kwak

Mi Kyung Son

Byong Moon Kim

Nam Gi Baik

Tae Young Oh

Byung Kwon Ryu

Hyunjoo Shim

Soonhoe Kim

Byong Ok Ahn

Gook Jun Ahn

Ghun Ii Lee

Hi Chang Yang

Jae Young Yu

Hadong Kim

Hae-Sun Kim

Yong Duck Kim

Tae Kyun Lim

Min Sun Chang

Miwon Son

Taeyoung Oh

Heungjae Kim

The present invention relates to an improved method for preparing dipeptidyl peptidase-IV inhibitor intermediates. The present invention is able to reduce preparation costs by using low cost reagents on reaction and is able to be used in mass production by improving yield.

Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate

The present invention relates to the pharmaceutical composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cells and acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.

Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative

The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.

Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate

The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.

Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients

Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose -regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero -order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug.

Method for preparing a biodegradable polymer microsphere containing a glucose-regulating peptide

The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug.

Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound

The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and bioavailability and therefore can be useful for the prophylaxis or treatment of DPP-IV-related diseases such as diabetes or obesity.

DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity

The present invention relates to 7-carboxymethyloxy-3',4&#x2032;,5-trimethoxy flavone.monohydrate which is a non hygroscopic product suitable for the preparation of metered dose of 7-carboxymethyloxy-3&#x2032;,4&#x2032;,5-trimethoxy flavone having protective activity for gastrointestinal tract including the colon, and a preparation method and uses thereof. 7-carboxymethyloxy-3&#x2032;,4&#x2032;,5-trimethoxy flavone.monohydrate of the present invention has advantages such as mucus protecting activity for gastrointestinal tract including the colon, convenience for handling and storage under ordinary humidity owing to its non-hygroscopicity, and ability to contain an active compound consistently for the formulation production of a medicine. In addition, the preparation method of 7-carboxymethyloxy-3&#x2032;,4&#x2032;,5-trimethoxy flavone.monohydrate of the present invention reduces long steps of total synthesis and requires mild conditions for the production of a compound because autoclave condition is not necessary for methylation in this case, and makes mass-production possible without any purification process such as recrystallization or column chromatography.

7-carboxymethyloxy-3',4&#x2032;,5-trimethoxy flavone monohydrate, the preparation method and uses thereof

The present invention relates to pyrazolopyrimidinone derivatives of formula 1, their preparation method and pharmaceutical compositions containing the said derivatives. The compounds have efficacy on the treatment of impotence, one of male sexual dysfunctions with the side effects reduced.

Pyrazolopyrimidinone derivatives for the treatment of impotence

Gastroprotective flavone/flavanone compounds with therapeutic effect on

Growing community of inventors

Seoul, South Korea

Moohi Yoo